May 21, 2026 06:19AM Leerink Starts Opus Genetics (IRD) at Outperform

May 13, 2026 05:06AM Opus Genetics (IRD) PT Lowered to $11 at Citizens on More Dilutive Shares in 10-Q

May 12, 2026 07:18AM Opus Genetics, Inc. (IRD) Misses Q1 EPS by 62c

May 5, 2026 04:21AM Opus Genetics (IRD) Reiterated at Market Outperform by Citizens

May 4, 2026 10:14AM Citizens Reiterates Market Outperform Rating on Opus Genetics (IRD) Ahead of Trial Data Presentation

Apr 28, 2026 02:25AM Citizens Starts Opus Genetics (IRD) at Market Outperform

Apr 21, 2026 06:10AM Opus Genetics (IRD) files for 7.37M share offering by selling stockholders

Apr 6, 2026 07:01AM Opus Genetics secures $155 million financing from Oberland Capital

Mar 30, 2026 06:14AM Cantor Fitzgerald Starts Opus Genetics (IRD) at Overweight

Mar 16, 2026 06:15AM Oppenheimer Starts Opus Genetics (IRD) at Outperform

Mar 12, 2026 06:48AM Opus Genetics (IRD) PT Raised to $10 at Wedbush

Mar 11, 2026 09:17AM Craig-Hallum Reiterates Buy Rating on Opus Genetics (IRD): "continue to see significant upside opportunity"

Mar 11, 2026 06:09AM H.C. Wainwright Reiterates Buy Rating on Opus Genetics (IRD)

Feb 25, 2026 06:59AM FDA accepts Opus Genetics presbyopia drug application

Feb 12, 2026 07:48AM LifeSci Capital Starts Opus Genetics (IRD) at Outperform

Jan 27, 2026 07:01AM Opus Genetics begins gene therapy trial for rare eye disease

Jan 20, 2026 05:06AM BTIG Starts Opus Genetics (IRD) at Buy

Jan 8, 2026 07:07AM Opus Genetics submits drug application, advances gene therapy trials

Dec 10, 2025 01:11AM B.Riley Starts Opus Genetics (IRD) at Buy

Dec 1, 2025 08:46AM Brookline Capital Markets Starts Opus Genetics (IRD) at Buy

Nov 25, 2025 03:54AM Piper Sandler Starts Opus Genetics (IRD) at Overweight

Nov 6, 2025 07:03AM Opus Genetics advances LCA5 gene therapy toward pivotal trial after FDA meeting

Oct 29, 2025 06:54AM Wedbush Starts Opus Genetics (IRD) at Outperform

Oct 16, 2025 07:53AM Chardan Capital Markets Starts Opus Genetics (IRD) at Buy

Oct 1, 2025 06:55AM H.C. Wainwright Reiterates Buy Rating on Opus Genetics (IRD)

Aug 18, 2025 08:01AM Opus Genetics receives FDA clearance for BEST1 gene therapy trial

Aug 13, 2025 06:13PM Opus Genetics, Inc. (IRD) Tops Q2 EPS by 7c

Jul 24, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Opus Genetics (IRD)

Jun 26, 2025 06:56AM Opus Genetics (IRD) Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint

Jun 25, 2025 05:19PM Opus Genetics (IRD) CFO departs; Amy Rabourn named interim principal financial officer

Jun 17, 2025 06:40AM Lucid Capital Markets Starts Opus Genetics (IRD) at Buy

Jun 2, 2025 08:00AM Opus Genetics (IRD) Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients

May 15, 2025 08:01AM Opus Genetics, Inc. (IRD) Tops Q1 EPS by 5c

May 6, 2025 08:03AM Opus Genetics (IRD) Granted FDA RMAT Designation for OPGx-LCA5 Gene Therapy Candidate

Apr 11, 2025 08:54AM Craig-Hallum Starts Opus Genetics (IRD) at Buy

Apr 8, 2025 08:01AM Opus Genetics (IRD) Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Apr 8, 2025 06:56AM Opus Genetics (IRD) Files for 19.38M Share Offering by Selling Stockholders

Apr 1, 2025 06:51AM H.C. Wainwright Reiterates Buy Rating on Opus Genetics (IRD)

Mar 21, 2025 09:12AM Opus Genetics (IRD) Prices $20M Share Offering, Concurrent Private Placement with Proceeds of Over $20M

Mar 19, 2025 03:57PM Opus Genetics (IRD) reports inducement awards

Feb 26, 2025 08:04AM Opus Genetics (IRD) Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Feb 18, 2025 07:30AM Opus Genetics (IRD) Announces Updates on OPGx-LCA5 Clinical Program

Dec 19, 2024 08:01AM Opus Genetics (IRD) Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330

Nov 13, 2024 06:52AM H.C. Wainwright Assumes Opus Genetics (IRD) at Buy

Nov 12, 2024 08:04AM Opus Genetics, Inc. (IRD) Misses Q3 EPS by 4c